期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ERCC1、RRM1及BRCA1在非小细胞肺癌中表达及其临床意义 被引量：6

下载PDF
导出
摘要 化疗是肺癌治疗的主要手段,耐药是影响化疗疗效的重要因素。近年来的研究表明,肿瘤细胞DNA修复的异常及其相关基因的表达异常使肿瘤对药物产生耐药是影响药效的一个重要因素。以下对肺癌常用化疗药物铂类、吉西他滨、紫杉类药物疗效相关的分子标志如ERCC1、RRM1、BRCA1等近年来的研究进展进行综述。
作者 殷柳 齐瑾 刘基巍
机构地区 大连医科大学附属第一医院肿瘤科
出处 《现代肿瘤医学》 CAS 2009年第4期788-791,共4页 Journal of Modern Oncology
关键词 化疗 耐药 基因检测 ERCC1 RRM1 BRCA1
分类号 R730.53 [医药卫生—肿瘤] R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献40

  • 1Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging[ J ]. Chest, 1997,111 : 1718 - 1723.
  • 2Arriagada R, Bergman B, Dunant A, et al. Cisplatin based adjuvant chemotherapy in patients with completely resected non - small - cell lung cancer[ J ]. N Engl J Med,2004,350 : 351 - 360.
  • 3Rosell R, Cecere F, Santarpia M,et al. Predicting the outcome of chemotherapy for lung cancer[ J ]. Curr Opin Pharmacol, 2006,6 : 323 -331.
  • 4Zhou W, Liu G, Park S, et al. Gene smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[ J]. Cancer Epidermal Biomarkers Prey, 2005,14 (2) :491 - 496.
  • 5Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non- small- cell lung cancer[ J]. Clin Cancer Res,2002 ,8 :2286 - 2291.
  • 6RoseU R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in non - small - cell lung cancer [ J ]. Lung Cancer , 2002, 38:217 - 227.
  • 7林莉,刘晓晴,宋三泰.DNA损伤修复与铂类耐药研究进展[J].中国肿瘤,2006,15(1):29-31. 被引量：29
  • 8Zhou W, Gurubhagavatnla S, Liu G, et al. Excision repair cresscomplementation group 1 polymorphism predicts overall survival in advanced non - small cell lung cancer patients treated with platinum - based chemotherapy[ J]. Clin Cancer Res,2004,10 ( 15 ) :4939- 4943.
  • 9RoseU R, Gandara D, Cobo M, et al. Customizing cisplatin based on quantitative excision repair cross - complementing 1 mRNA expression: A phase Ⅲ randomized trial in non - small cell lung cancer [ C ]. The 31 st Congress of the European Society of Medical Oncology, Turkey: Instanbul,2003.
  • 10Olaussen KA, Ariane D, Fouret P, et al. DNA repair by ERCC1 in non- small - cell lung cancer and cisplatin - based adjuvant chemotherapy[J]. N Engl J Med, 2006,355:983 -991.

二级参考文献45

  • 1Rosell R, Predictive molecular markers in non-small cell lung cancer[J]. Curr Opin Oncol, 2001,13:101-109.
  • 2Hou SM, Ryk C, Kannio A, et al. Influence of common XPD and XRCCI variant alleles on p53 mutations in lung tumors[J]. Environ Mol Mutagen,2003,41 (1):37-42.
  • 3Gurubhagavatula S, Liu G, Park S, et al. XPD and XR-CC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy [J]. J Clin Oncol, 2004,22(13):2594-2601.
  • 4Rosell R Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell Rung cancer [J]. Cancer Control, 2003,10(4):297-305.
  • 5Rosell R, Taron M, Camps C. Influence of genetic markers on survival in non-small cell lung cancer[J]. Dnlgs Toclay (Barc), 2003,39(10):775-786.
  • 6Rosell R. Determinants of response and resistance of cytotoxics[J]. Semin Oncol, 2002, 29(1 Suppl 4):110-118.
  • 7David JP, Stoehlmacher J, Wu Zhang, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemptherapy in patients with advanced colorectal cancer [J]. Cancer Research,2001.15: 8654-8658.
  • 8Yu HP, Wang XL, Sun X, et al. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma [J]. Cancer Genet Cytogenet,2004,154(1):10-15.
  • 9Rosell R, Crino L, Danenberg K,et al.Targeted therapy in combination with gemcitabine in non-small cell lung cancer[Jl.Semin Oncol, 2003,30(4 Suppl 10):19-25.
  • 10Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-Fu/oxaliplatin combination chemotherapy in refractory colorectal cancer[J]. Br J Cancer, 2004,91(2):344-354.

共引文献37

同被引文献52

  • 1陈建,李敏伟,张国兵,李菌,王临润.SYBR荧光实时定量PCR检测非小细胞肺癌组织与外周血中RRM1和ERCC1及BRCA1基因表达水平[J].浙江大学学报（医学版）,2010,39(6):628-633. 被引量：8
  • 2曾敬,饶慧兰,张惠忠,侯景辉,吴惠茜,赵美卿.细胞骨架蛋白tubulin α、β在不同级别胶质瘤中的表达及其与预后的相关性[J].实用肿瘤杂志,2005,20(6):497-499. 被引量：6
  • 3Rosell R,Lord R V,Taron M,et al.DNA repair and cisplatin resistance in non-small-cell lung cancer[J].Lung cancer,2002,38(3):217-227.
  • 4Sarries C,Haura E B,Roig B,et al.Pharmacogenomics strategies for developing customized chemotherapy in non-small cell lung cancer[J].Pharmacogenomics,2002,3(6):763-780.
  • 5Shirota Y,Stoehlmacher J,Brabender J,et al.ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracilChemotherapy[J].Clin Oncol,2001,19(23):4298-4304.
  • 6Lord R V N,Brabender J,Gandara D,et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer[J].Clin Cancer Res,2002,8:2286-2291.
  • 7Rosell R,Pifarre A,Monzo M,et al.Reduced survival in patients with stage-Ⅰ non-small-cell lung cancer associated with DNA-replication errore[J].Int J Cancer,1997,74(3):330-333.
  • 8Bepler G,Gautam A,Mclntyre L N,et al.Prognostic significance of molecular genetic aberration on chromosome segment 11p15.5 in non-small cell lung cancer[J].J Clin Oncol,2002,20(5):1353-1360.
  • 9Rosell R,Cobo M,Isla D,et al.ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin(cis) or gemcitabine (gem)in stageⅣ non-small-cell Lung cancer(N SCLC) patients[J].J Clin Oncol,2005,23(suppl 1):7002.
  • 10Olaussen K A,Ariane D,Fouret P,et al.DNA repair by ERCCl in Non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,355(10):983-991.

引证文献6

二级引证文献23

现代肿瘤医学
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部